Table 4 The summary of studies of HAG regimen for AML, high-risk MDS and MDS/AML
From: Homoharringtonine and omacetaxine for myeloid hematological malignancies
Reference | Patients type | No. | CR, % |
|---|---|---|---|
Wei 2006 [[76]] | Refractory or relapsed AML | 20 | 70.0 |
Zhang 2008 [[77]] | Refractory or relapsed AML | 36 | 50.0 |
Ji 2010 [[78]] | Refractory or relapsed AML | 37 | 46.0 |
Gu 2011 [[79]] | Refractory or relapsed AML | 67 | 52.2 |
Liu 2006 [[80]] | Elderly AML | 31 | 58.1 |
Shu 2007 [[84]] | MDS-RAEB | 28 | 53.6 |
Su 2008 [[85]] | High-risk MDS or MDS/AML | 33 | 46.7 |
Wu 2009 [[86]] | High-risk MDS or MDS/AML | 32 | 46.9 |
Wu 2011 [[87]] | Elderly high-risk MDS or MDS/AML | 33 | 57.6 |